J. Tibble et al., Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma, GUT, 49(3), 2001, pp. 402-408
Background and aims-Testing for faecal occult blood has become an accepted
technique of non-invasive screening for colorectal neoplasia but lack of se
nsitivity remains a problem. The aim of this study was to compare the sensi
tivity and specificity of faecal calprotectin and faecal occult blood in pa
tients with colorectal cancer and colonic polyps.
Methods-Faecal calprotectin and occult blood were assessed in 62 patients w
ith colorectal carcinoma and 233 patients referred for colonoscopy. The ran
ge of normality for faecal calprotectin (0.5-10.5 mg/l) was determined from
96 healthy subjects.
Results-Median faecal calprotectin concentration in the 62 patients with co
lorectal carcinoma (101 mg/l, 95% confidence interval (CI) 57-133) differed
significantly from normal (2.3 mg/l, 95% CI 1.6-5.0) with 90% of patients
having elevated levels (normal <10 mg/l) whereas only 36/62 (58%) had posit
ive faecal occult bloods. There was no significant difference in faecal cal
protectin levels when considering location or Dukes' staging of tumour. Per
centage positivity of faecal occult bloods was significantly higher for Duk
es' stage C and D cancers compared with Dukes' A and B. In the colonoscopy
group, 29 patients with adenomatous polyps were detected in whom the median
faecal calprotectin was 12 mg/l (95% CI 2.9-32). Sensitivity for detection
of adenomatous polyps was 55% using the calprotectin method and 10% using
faecal occult blood testing. The overall sensitivity and specificity of cal
protectin for colorectal cancer and adenomatous polyps as a combined group
was 79% and 72%, respectively, compared with a sensitivity and specificity
of faecal occult blood of 43% and 92%.
Conclusions-Faecal calprotectin is a simple and sensitive non-invasive mark
er of colorectal cancer and adenomatous polyps. It is more sensitive than f
aecal occult blood tests for detection of colorectal neoplasia at the cost
of a somewhat lower specificity.